The aim of this study was to evaluate the prognostic value of tissue polypeptide specific antigen (TPS) in non-small cell lung cancer. A prospective study included 187 patients with NSCLC. Results: The overal survival was 11,5 months. In the group of patients with high TPS level, the median survival was 9,8 months, in the group of patients with normal TPS level, the median survival was 14,2 months. TPS has independent prognostic value for survival in the patients with non-small cell lung cancer.